DTCFF (Defence Therapeutics) Interest Expense: $-0.16 Mil (TTM As of Mar. 2026)


DTCFF Defence Therapeutics Inc DTCFF
25 GF Score
Price $0.31
! 1 Warning Sign
View Full Analysis

What is Defence Therapeutics Interest Expense?

Defence Therapeutics DTCFF +2.33% 25 Interest Expense is $-0.16 Mil as of Mar. 2026. GuruFocus rates DTCFF with a GF Score™ of 25/100. The stock has 1 warning sign investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Defence Therapeutics's interest expense for the three months ended in Mar. 2026 was $ -0.06 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.16 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Defence Therapeutics's Operating Income for the three months ended in Mar. 2026 was $ -1.03 Mil. Defence Therapeutics's Interest Expense for the three months ended in Mar. 2026 was $ -0.06 Mil. Defence Therapeutics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Defence Therapeutics  (OTCPK:DTCFF) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Defence Therapeutics's Interest Expense for the three months ended in Mar. 2026 was $-0.06 Mil. Its Operating Income for the three months ended in Mar. 2026 was $-1.03 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was $1.14 Mil.

Defence Therapeutics's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Defence Therapeutics did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Defence Therapeutics Interest Expense Historical Data

* Premium members only.

The historical data trend for Defence Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Defence Therapeutics Interest Expense Chart

Defence Therapeutics Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Interest Expense
Get a 7-Day Free Trial 0.00 0.00 -0.20 -0.29 -0.24

Defence Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.06 -0.02 -0.01 -0.08 -0.06
DTCFF
25GF Score
Defence Therapeutics Inc DTCFF
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Defence Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.16 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of $-0.16 Mil mean?
Defence Therapeutics (DTCFF) has a Interest Expense of $-0.16 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Defence Therapeutics and its competitors.
Is Defence Therapeutics' Interest Expense too high?
Defence Therapeutics' current Interest Expense is $-0.16 Mil. Overall, Defence Therapeutics has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Defence Therapeutics' Interest Expense compare to VRTX and REGN?
Defence Therapeutics' Interest Expense of $-0.16 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Defence Therapeutics and its competitors. Defence Therapeutics's current Interest Expense is $-0.16 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Defence Therapeutics stock overvalued right now?
Defence Therapeutics (DTCFF) has a current Interest Expense of $-0.16 Mil. The current Interest Expense is $-0.16 Mil. Defence Therapeutics' overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Defence Therapeutics (DTCFF), the current Interest Expense is $-0.16 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Defence Therapeutics Business Description

Other Exchanges DTC:GermanyDTC:Canada
Address 7171 Frederick Banting Street, Montreal, QC, CAN, H4S 1Z9
Defence Therapeutics Inc is engaged in the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The Company has one operating segment, being research and development. It operates only in Canada.
25GF Score

Get the complete analysis for DTCFF

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.31
Price